Ironwood Pharmaceuticals Total Long Term Liabilities 2010-2024 | IRWD

Ironwood Pharmaceuticals total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Ironwood Pharmaceuticals Annual Total Long Term Liabilities
(Millions of US $)
2023 $541
2022 $423
2021 $359
2020 $464
2019 $455
2018 $409
2017 $530
2016 $552
2015 $448
2014 $180
2013 $200
2012 $31
2011 $34
2010 $77
2009 $404
Ironwood Pharmaceuticals Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $651
2024-06-30 $672
2024-03-31 $517
2023-12-31 $541
2023-09-30 $569
2023-06-30 $645
2023-03-31 $425
2022-12-31 $423
2022-09-30 $422
2022-06-30 $420
2022-03-31 $418
2021-12-31 $359
2021-09-30 $354
2021-06-30 $361
2021-03-31 $466
2020-12-31 $464
2020-09-30 $454
2020-06-30 $454
2020-03-31 $448
2019-12-31 $455
2019-09-30 $435
2019-06-30 $424
2019-03-31 $482
2018-12-31 $409
2018-09-30 $501
2018-06-30 $567
2018-03-31 $527
2017-12-31 $530
2017-09-30 $578
2017-06-30 $620
2017-03-31 $593
2016-12-31 $552
2016-09-30 $577
2016-06-30 $528
2016-03-31 $434
2015-12-31 $448
2015-09-30 $445
2015-06-30 $452
2015-03-31 $178
2014-12-31 $180
2014-09-30 $184
2014-06-30 $188
2014-03-31 $191
2013-12-31 $200
2013-09-30 $202
2013-06-30 $201
2013-03-31 $204
2012-12-31 $31
2012-09-30 $29
2012-06-30 $31
2012-03-31 $33
2011-12-31 $34
2011-09-30 $36
2011-06-30 $49
2011-03-31 $67
2010-12-31 $77
2010-09-30 $81
2010-06-30 $91
2010-03-31 $94
2009-12-31 $404
2009-09-30 $374
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.621B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $73.775B 28.39
Chugai Pharmaceutical (CHGCY) Japan $70.198B 27.35
Takeda Pharmaceutical (TAK) Japan $41.396B 8.62
Merck (MKKGY) Germany $18.461B 16.53
Sandoz Group AG (SDZNY) Switzerland $18.159B 0.00
Astellas Pharma (ALPMY) Japan $17.463B 16.08
United Therapeutics (UTHR) United States $16.079B 15.82
Neurocrine Biosciences (NBIX) United States $13.664B 36.18
Summit Therapeutics (SMMT) United States $13.569B 0.00
Shionogi (SGIOY) Japan $11.688B 11.71
Madrigal Pharmaceuticals (MDGL) United States $6.399B 0.00
Orion OYJ (ORINY) Finland $6.196B 17.42
Ionis Pharmaceuticals (IONS) United States $5.620B 0.00
Corcept Therapeutics (CORT) United States $5.359B 40.60
Crinetics Pharmaceuticals (CRNX) United States $4.891B 0.00
PTC Therapeutics (PTCT) United States $3.490B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.560B 11.60
Dyne Therapeutics (DYN) United States $2.473B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.401B 14.35
NewAmsterdam Pharma (NAMS) Netherlands $2.352B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.314B 0.00
Soleno Therapeutics (SLNO) United States $1.949B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.746B 0.00
Xencor (XNCR) United States $1.680B 0.00
Indivior (INDV) United States $1.591B 6.48
Evotec AG (EVO) Germany $1.559B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.531B 0.00
Guardian Pharmacy Services (GRDN) United States $1.382B 0.00
Ocular Therapeutix (OCUL) United States $1.328B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.294B 0.00
Harrow (HROW) United States $1.226B 0.00
Enliven Therapeutics (ELVN) United States $1.117B 0.00
Ardelyx (ARDX) United States $1.111B 0.00
ARS Pharmaceuticals (SPRY) United States $1.100B 0.00
Collegium Pharmaceutical (COLL) United States $0.982B 5.36
Avadel Pharmaceuticals (AVDL) Ireland $0.974B 0.00
Bioventus (BVS) United States $0.854B 26.97
Oruka Therapeutics (ORKA) United States $0.727B 0.00
Cronos Group (CRON) Canada $0.715B 0.00
Relay Therapeutics (RLAY) United States $0.713B 0.00
USANA Health Sciences (USNA) United States $0.662B 12.27
Elite Pharmaceuticals (ELTP) United States $0.609B 0.00
Altimmune (ALT) United States $0.582B 0.00
Savara (SVRA) United States $0.554B 0.00
Tourmaline Bio (TRML) United States $0.522B 0.00
Xeris Biopharma Holdings (XERS) United States $0.508B 0.00
OmniAb (OABI) United States $0.494B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.478B 0.00
Zevra Therapeutics (ZVRA) United States $0.456B 0.00
Verve Therapeutics (VERV) United States $0.437B 0.00
Siga Technologies (SIGA) United States $0.431B 5.03
Esperion Therapeutics (ESPR) United States $0.429B 0.00
ProKidney (PROK) United States $0.426B 0.00
Organogenesis (ORGO) United States $0.412B 0.00
Korro Bio (KRRO) United States $0.404B 0.00
KalVista Pharmaceuticals (KALV) United States $0.400B 0.00
Akebia Therapeutics (AKBA) United States $0.391B 0.00
Aquestive Therapeutics (AQST) United States $0.332B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.303B 122.93
Avita Medical (RCEL) United States $0.301B 0.00
Aldeyra Therapeutics (ALDX) United States $0.289B 0.00
Nature's Sunshine Products (NATR) United States $0.280B 16.63
Amylyx Pharmaceuticals (AMLX) United States $0.271B 0.00
4D Molecular Therapeutics (FDMT) United States $0.267B 0.00
Larimar Therapeutics (LRMR) United States $0.254B 0.00
Heron Therapeutics (HRTX) United States $0.233B 0.00
Innate Pharma SA (IPHYF) France $0.233B 0.00
Profound Medical (PROF) Canada $0.219B 0.00
Inhibikase Therapeutics (IKT) United States $0.212B 0.00
Acrivon Therapeutics (ACRV) United States $0.208B 0.00
Lexeo Therapeutics (LXEO) United States $0.200B 0.00
Aclaris Therapeutics (ACRS) United States $0.198B 0.00
Silence Therapeutics (SLN) United Kingdom $0.190B 0.00
Lyell Immunopharma (LYEL) United States $0.187B 0.00
MediWound (MDWD) Israel $0.186B 0.00
Nektar Therapeutics (NKTR) United States $0.174B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.162B 0.00
Nanobiotix S.A (NBTX) France $0.155B 0.00
CytoDyn (CYDY) United States $0.150B 0.00
Metagenomi (MGX) United States $0.144B 0.00
VAXART, INC (VXRT) United States $0.137B 0.00
Telomir Pharmaceuticals (TELO) United States $0.134B 0.00
Achieve Life Sciences (ACHV) Canada $0.131B 0.00
Galectin Therapeutics (GALT) United States $0.126B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Cassava Sciences (SAVA) United States $0.110B 0.00
Cardiol Therapeutics (CRDL) Canada $0.107B 0.00
Protara Therapeutics (TARA) United States $0.107B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.107B 0.00
Champions Oncology (CSBR) United States $0.104B 0.00
Regulus Therapeutics (RGLS) United States $0.102B 0.00
Inotiv (NOTV) United States $0.100B 0.00
Journey Medical (DERM) United States $0.097B 0.00
ElectroCore (ECOR) United States $0.095B 0.00
Avalo Therapeutics (AVTX) United States $0.094B 0.00
Pyxis Oncology (PYXS) United States $0.092B 0.00
Century Therapeutics (IPSC) United States $0.089B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Karyopharm Therapeutics (KPTI) United States $0.082B 0.00
Context Therapeutics (CNTX) United States $0.082B 0.00
Assertio Holdings (ASRT) United States $0.080B 21.08
Arch Biopartners (ACHFF) Canada $0.078B 0.00
PMV Pharmaceuticals (PMVP) United States $0.078B 0.00
Unicycive Therapeutics (UNCY) United States $0.074B 0.00
ESSA Pharma (EPIX) Canada $0.071B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Scienture Holdings (SCNX) United States $0.070B 0.00
OptiNose (OPTN) United States $0.064B 0.00
Mural Oncology (MURA) Ireland $0.053B 0.00
AlloVir (ALVR) United States $0.052B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.050B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Iterum Therapeutics (ITRM) Ireland $0.048B 0.00
Nutriband (NTRB) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.044B 0.00
Gain Therapeutics (GANX) United States $0.042B 0.00
CASI Pharmaceuticals (CASI) China $0.042B 0.00
SCYNEXIS (SCYX) United States $0.038B 0.00
BioVie (BIVI) United States $0.037B 0.00
FibroGen (FGEN) United States $0.036B 0.00
VYNE Therapeutics (VYNE) United States $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.033B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.033B 0.00
Surrozen (SRZN) United States $0.032B 0.00
Incannex Healthcare (IXHL) Australia $0.031B 0.00
Tempest Therapeutics (TPST) United States $0.031B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
DURECT (DRRX) United States $0.027B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Lipocine (LPCN) United States $0.025B 0.00
Vivos Therapeutics (VVOS) United States $0.023B 0.00
Mannatech (MTEX) United States $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
NRx Pharmaceuticals (NRXP) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
MEI Pharma (MEIP) United States $0.016B 0.00
BioLineRx (BLRX) Israel $0.016B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.013B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.013B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Nuvilex (PMCB) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Relmada Therapeutics (RLMD) United States $0.011B 0.00
Talphera (TLPH) United States $0.011B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Indaptus Therapeutics (INDP) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Viracta Therapeutics (VIRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Dominari Holdings (DOMH) United States $0.008B 0.00
Redhill Biopharma (RDHL) Israel $0.008B 0.00
CERo Therapeutics Holdings (CERO) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
Conduit Pharmaceuticals (CDT) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
Biomerica (BMRA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.10
SHINECO (SISI) China $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
TransCode Therapeutics (RNAZ) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Molecular Templates (MTEM) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Phio Pharmaceuticals (PHIO) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
Jupiter Neurosciences (JUNS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 4.69
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 41.84